for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK.N

Latest Trade

88.56USD

Change

-1.09(-1.22%)

Volume

3,185,708

Today's Range

88.26

 - 

89.58

52 Week Range

72.06

 - 

92.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Myriad Submits sPMA for BRACAnalysis CDx as a Companion Diagnostic for Lynparza

Jan 21 (Reuters) - Myriad Genetics Inc <MYGN.O>::MYRIAD SUBMITS SPMA FOR BRACANALYSIS® CDX AS A COMPANION DIAGNOSTIC FOR LYNPARZA® IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.MYRIAD GENETICS - HAS SUBMITTED SUPPLEMENTARY PREMARKET APPROVAL APPLICATION TO U.S. FDA FOR BRACANALYSIS CDX TEST AS COMPANION DIAGNOSTIC TO LYNPARZA.

FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Lynparza

Jan 21 (Reuters) - Merck & Co Inc <MRK.N>::FDA ACCEPTS REGULATORY SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LYNPARZA® (OLAPARIB) IN HRR-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND GRANTS PRIORITY REVIEW.MERCK & CO INC - A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE IS SET FOR Q2 OF 2020 FOR LYNPARZA.MERCK & CO INC - SNDA ACCEPTANCE FOR REVIEW BY FDA IS BASED ON POSITIVE RESULTS FROM PHASE 3 PROFOUND TRIAL.

FDA Accepts Regulatory Submission Of Supplemental New Drug Application For Lynparza

Jan 13 (Reuters) - Merck & Co Inc <MRK.N>::FDA ACCEPTS REGULATORY SUBMISSION OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LYNPARZA® (OLAPARIB) AS FIRST-LINE MAINTENANCE WITH BEVACIZUMAB IN ADVANCED OVARIAN CANCER AND GRANTS PRIORITY REVIEW.MERCK & CO INC - A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE IS SET FOR Q2 OF 2020.MERCK - SNDA SUBMISSION FOR LYNPARZA (OLAPARIB) AS FIRST-LINE MAINTENANCE WITH BEVACIZUMAB IN ADVANCED OVARIAN CANCER BASED ON PAOLA-1 TRIAL.

U.S. FDA approves Merck's Keytruda for bladder cancer

Jan 8 (Reuters) - Merck & Co Inc <MRK.N>::FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR PATIENTS WITH BCG-UNRESPONSIVE, HIGH-RISK, NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU WITH OR WITHOUT PAPILLARY TUMORS WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY.

FDA Approves Pembrolizumab For BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

Jan 8 (Reuters) - FDA::FDA APPROVES PEMBROLIZUMAB FOR BCG-UNRESPONSIVE, HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER.

GenOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance

Jan 7 (Reuters) - GENOWAY <ALGEN.PA>::GENOWAY EXTENDS ITS STRATEGIC ALLIANCE WITH MERCK .GENOWAY ACQUIRES ADDITIONAL RIGHTS TO DEVELOP ALL ANIMAL CELL MODELS USING THE CRISPR/CAS9 SYSTEM.LICENSE PROVIDES GENOWAY WITH NON-EXCLUSIVE RIGHTS TO COMMERCIALIZE DEVELOPMENT AND USE OF ALL OTHER ANIMAL CELL MODELS FOR ITS CUSTOMERS' INTERNAL RESEARCH USES AS WELL AS COMMERCIAL EXPLOITATION.

BRIEF-Merck's Keytruda Shows Mixed Results In Phase 3 Trial For Small Cell Lung Cancer

Corrects headline to say Keytruda shows mixed results instead of significantly improving survival:MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED TO CHEMOTHERAPY ALONE AS FIRST-LINE TREATMENT FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER.MERCK & CO INC - PHASE 3 KEYNOTE-604 STUDY DID NOT MEET OTHER DUAL PRIMARY ENDPOINT OF OVERALL SURVIVAL.MERCK - PHASE 3 KEYNOTE-604 TRIAL INVESTIGATING KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY MET ONE OF DUAL PRIMARY ENDPOINTS OF PROGRESSION-FREE SURVIVAL.MERCK - TREATMENT WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY RESULTED IN STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS VERSUS CHEMOTHERAPY ALONE.MERCK & CO INC - THERE WAS IMPROVEMENT IN OS FOR PATIENTS TREATED WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY COMPARED TO CHEMOTHERAPY ALONE.MERCK & CO INC - OS RESULTS DID NOT MEET STATISTICAL SIGNIFICANCE PER PRE-SPECIFIED STATISTICAL PLAN.

Merck Establishes Strategic Oncology Collaboration With Taiho And Astex

Jan 6 (Reuters) - Merck & Co Inc <MRK.N>::MERCK ESTABLISHES STRATEGIC ONCOLOGY COLLABORATION WITH TAIHO AND ASTEX.MERCK & CO INC - TAIHO AND ASTEX WILL RECEIVE AN AGGREGATE UPFRONT PAYMENT OF $50 MILLION.MERCK & CO INC - CO, TAIHO, ASTEX WILL COMBINE PRECLINICAL CANDIDATES, THEIR DATA WITH KNOWLEDGE AND EXPERTISE FROM RESPECTIVE RESEARCH PROGRAMS.MERCK - ANNOUNCED EXCLUSIVE WORLDWIDE RESEARCH COLLABORATION & LICENSE AGREEMENT WITH TAIHO PHARMACEUTICAL & ASTEX PHARMACEUTICALS (UK).MERCK - TAIHO & ASTEX TO BE ELIGIBLE TO GET ABOUT $2.5 BILLION CONTINGENT UPON ACHIEVEMENT OF SOME MILESTONES FOR MULTIPLE PRODUCTS ARISING FROM AGREEMENT.MERCK - UNDER COLLABORATION WITH TAIHO AND ASTEX, CO WILL FUND RESEARCH AND DEVELOPMENT AND WILL BE RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS GLOBALLY.MERCK - TAIHO HAS RETAINED CO-COMMERCIALIZATION RIGHTS IN JAPAN, OPTION TO PROMOTE IN SPECIFIC AREAS OF SOUTH EAST ASIA.

U.S. FDA Announces First FDA-Approved Vaccine For The Prevention Of Ebola Virus Disease

Dec 19 (Reuters) - :FIRST FDA-APPROVED VACCINE FOR THE PREVENTION OF EBOLA VIRUS DISEASE, MARKING A CRITICAL MILESTONE IN PUBLIC HEALTH PREPAREDNESS AND RESPONSE.U.S. FDA SAYS APPROVAL OF ERVEBO WAS GRANTED TO MERCK & CO.

PDS Biotechnology Announces Principal Investigator And Independent Data Monitoring Committee For Its Phase 2 Clinical Collaboration With Merck

Dec 11 (Reuters) - PDS Biotechnology Corp <PDSB.O>::PDS BIOTECHNOLOGY ANNOUNCES PRINCIPAL INVESTIGATOR AND INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PHASE 2 CLINICAL COLLABORATION WITH MERCK.PDS BIOTECHNOLOGY CORP - JARED WEISS WILL BE PRINCIPAL INVESTIGATOR FOR CO'S PHASE 2 VERSATILE-002 STUDY IN COLLABORATION WITH MERCK.PDS BIOTECHNOLOGY CORP - COMBINATION STUDY IS EXPECTED TO BE INITIATED IN NEXT THREE TO FOUR MONTHS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up